Foster Victor Wealth Advisors LLC Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Foster Victor Wealth Advisors LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 13.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,766 shares of the company’s stock after acquiring an additional 9,827 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $12,022,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the period. Finally, Activest Wealth Management bought a new stake in Johnson & Johnson during the 3rd quarter valued at $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $152.09 on Friday. The stock has a market cap of $366.17 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 2.43 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a 50 day simple moving average of $147.61 and a two-hundred day simple moving average of $156.09. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.26%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

JNJ has been the topic of several research reports. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Wells Fargo & Company lowered their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.